United Therapeutics Corporation Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

19:54 EDT 11 Oct 2018 | BioPortfolio Reports

United Therapeutics Corporation Strategy, SWOT and Corporate Finance Report


Summary


United Therapeutics Corporation Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.


Key Highlights


United Therapeutics Corporation United Therapeutics or 'the company' is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life threatening conditions. The product portfolio of the company includes Remodulin Injection; Tyvaso treprostinil Inhalation Solution; Adcirca tadalafil Tablets; Orenitram treprostinil extended release tablets; PLX Cells; Replacement Lungs Transplantation and SelfInjectable Prostacyclin Analogues PAH. United Therapeutics sells its products through specialty pharmaceutical distributors in the US. The company operates in Europe, Israel and the Middle East, Asia and South and Central America. United Therapeutics is headquartered in Silver Spring, Maryland, the US.


Scope


Detailed information on United Therapeutics Corporation required for business and competitor intelligence needs

A study of the major internal and external factors affecting United Therapeutics Corporation in the form of a SWOT analysis

An indepth view of the business model of United Therapeutics Corporation including a breakdown and examination of key business segments

Intelligence on United Therapeutics Corporation's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about United Therapeutics Corporation, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends


Reasons to buy


Gain understanding of United Therapeutics Corporation and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess United Therapeutics Corporation as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on United Therapeutics Corporation's business structure, strategy and prospects.

More From BioPortfolio on "United Therapeutics Corporation Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175"